Symyoo Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Yongsan Korea, Republic of (2019)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Symyoo

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colonic Diseases (Phase 3)

Fatigue (Phase 3)

Fatigue Syndrome, Chronic (Phase 3)

Neutropenia (Phase 3)

Premature Birth (Phase 3)

Premature Ejaculation (Phase 3)

Sepsis (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Syndrome (Phase 3)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 10